UNSPSC 51273301: Cinoctramide

This classification denotes an anesthetic agent with the molecular formula C19H27NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 69J8AO72Q3, chemically known as octahydro-1-(3,4,5-trimethoxycinnamoyl)azocine. but generally known as cinoctramide, which bears US NIH Compound Identifier 6443803. European Medicines Agency schedules Cinoctramide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06306MIG.

UNSPSC 51273301 Cinoctramide is a Commodity code that in practice encompasses pharmaceutical products and related health-delivery systems procured by state and local health authorities, though the recent opportunities tagged to this code show substantial scope drift. The three most recent state and local solicitations under this code include Seminole County, Florida seeking naloxone and drug deactivation systems; the Texas Health and Human Services Commission conducting market research on direct-to-manufacturer pharmacy programs; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issuing an RFP for generic multi-source pharmaceuticals and over-the-counter products across participating state and local facilities including Oregon. The mix of issuing bodies spans county health departments, state HHS commissions, and cooperative purchasing alliances that aggregate demand across multiple jurisdictions. The actual procurement scope is fragmented—the code appears to be applied inconsistently to health-related goods ranging from naloxone kits to generic pharmaceuticals to pharmacy program infrastructure, rather than to cinoctramide specifically.

Geographically, recent activity clusters in Florida (Seminole County IFB), Texas (HHS RFI), and Minnesota (MMCAP RFP with Oregon participation). Seminole County's IFB 60459723LAS, due July 26, 2023, seeks 1,900 units of naloxone and 800 drug deactivation systems annually with quarterly deliveries to Sanford, Florida under a two-year contract with one-year renewal option. The Texas HHS Commission's RFI HHS0017013, posted April 3, 2026, is a preliminary market-intelligence solicitation exploring vendor capacity for direct-to-manufacturer prescription fulfillment outside traditional pharmacy benefit manager channels. MMCAP's RFP S1070000015802, due March 26, 2026, establishes multi-award contracts for generic pharmaceuticals and OTC products distributed through three authorized wholesalers (Cencora, Cardinal Health, Morris & Dickson), with contract term of two years effective July 1, 2026, and evaluation weighted 75 percent on price competitiveness. The code shows limited recent activity tagged specifically to cinoctramide; most opportunities involve broader pharmaceutical procurement programs.